In ROC analysis, PRSS1 showed good diagnostic value in acute leukemia patients and in ALL patients, and very good diagnostic value in AML patients, nominating it as a promising diagnostic biomarker for acute leukemias, especially AML. This evidence concerns the gene PRSS1 and acute lymphoblastic leukemia.